Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets

10Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

Abstract

Multiple sclerosis (MS) is an autoimmune-mediated demyelinating disease of the central nervous system. The main pathological features are inflammatory reaction, demyelination, axonal disintegration, reactive gliosis, etc. The etiology and pathogenesis of the disease have not been clarified. The initial studies believed that T cell-mediated cellular immunity is the key to the pathogenesis of MS. In recent years, more and more evidence has shown that B cells and their mediated humoral immune and innate immune cells (such as microglia, dendritic cells, macrophages, etc.) also play an important role in the pathogenesis of MS. This article mainly reviews the research progress of MS by targeting different immune cells and analyzes the action pathways of drugs. The types and mechanisms of immune cells related to the pathogenesis are introduced in detail, and the mechanisms of drugs targeting different immune cells are discussed in depth. This article aims to clarify the pathogenesis and immunotherapy pathway of MS, hoping to find new targets and strategies for the development of therapeutic drugs for MS.

Cite

CITATION STYLE

APA

Ma, X., Ma, R., Zhang, M., Qian, B., Wang, B., & Yang, W. (2023, March 1). Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets. Pharmaceutics. MDPI. https://doi.org/10.3390/pharmaceutics15030728

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free